

To

Date: 04.02.2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636)

Sub: Outcome of Board Meeting and other matters under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Oxygenta Pharmaceutical Limited**, at its Meeting held on Wednesday, 04th February, 2026, at 12:00 noon at the corporate office of the Company, considered and approved the following:

1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (**Attached as Annexure**)
2. Limited Review Report for the quarter and nine months ended 31.12.2025. (**Attached as Annexure**)
3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH Act) w.e.f., 04.02.2026. (**Attached as Annexure -I**)

The Meeting concluded at 5:50 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Oxygenta Pharmaceutical Limited

Balasubba Reddy Mamilla
Whole-time Director
(DIN: 01998852)

Annexure – I
Composition of Internal Complaints Committee (ICC)/POSH Committee

| S no. | Name of the Member(s) | Designation |
|--------------|------------------------------|--------------------|
| 1. | Mrs. G. Durga Bhavani | Presiding Officer |
| 2. | Mr. M. Sreedhar Reddy | Internal Member |
| 3. | Mr. P. Nikhil Reddy | Internal Member |
| 4. | Mr. K. Mahesh | Member |
| 5. | Mr. S. Chandraleka | Member |
| 6. | B. Rajitha | Member |
| 7. | K. Divya | Member |
| 8. | Ms. D. Rajeswari | External Member |

OXYGENTA PHARMACEUTICAL LIMITED

CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2025

(Rupees in Lakhs except for EPS)

| S. No | Particulars | Quarter Ended | | | Nine months Ended | | YEAR ENDED |
|--------------|---|---------------|-------------|-------------|-------------------|-------------|------------|
| | | 31/12/2025 | 30/09/2025 | 31/12/2024 | 31/12/2025 | 31/12/2024 | 31-03-2025 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Income from Operations | | | | | | |
| | (a) Net Sales/Income from Operations (net of excise duty) | 3,393.09 | 1,430.23 | 3,320.61 | 6,336.79 | 5,983.21 | 10,929.86 |
| | (b) Other Operating Income | - | (5.62) | 48.82 | 11.29 | 126.00 | 130.91 |
| | Total income from operations (net) | 3,393.09 | 1,424.61 | 3,369.43 | 6,348.08 | 6,109.21 | 11,060.77 |
| 2 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 3,117.03 | 1,696.51 | 3,760.65 | 6,379.42 | 5,620.10 | 10,023.06 |
| | (b) Purchase of stock-in-trade | - | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, work-in-progress and stock | 36.98 | (452.80) | (576.22) | (486.16) | (351.73) | (376.06) |
| | (d) Direct Manufacturing Expenses | 376.91 | 379.34 | 320.95 | 1,142.43 | 771.73 | 1,116.09 |
| | (e) Employee benefit expense | 189.04 | 203.47 | 183.28 | 592.70 | 470.96 | 684.70 |
| | (f) Finance Costs | 139.08 | 94.96 | 38.83 | 296.88 | 148.60 | 361.42 |
| | (g) Depreciation and amortisation expense | 85.92 | 85.71 | 70.60 | 256.36 | 201.53 | 178.16 |
| | (h) Other expenses | 80.79 | 61.20 | 67.52 | 256.51 | 303.23 | 476.51 |
| | (i) Prior Period Expense | | | | | - | 5.02 |
| | Total expenses | 4,025.74 | 2,068.39 | 3,865.60 | 8,438.13 | 7,164.42 | 12,468.91 |
| 3 | Profit from operations before other income and exceptional items (1-2) | (632.65) | (643.78) | (496.18) | (2,090.05) | (1,055.22) | (1,408.14) |
| 4 | Other income | - | - | - | - | - | - |
| 5 | Profit from ordinary activities before exceptional items (3+4) | (632.65) | (643.78) | (496.18) | (2,090.05) | (1,055.22) | (1,408.14) |
| 6 | Exceptional (expenses)/income | | | - | (4.64) | - | (27.00) |
| 7 | Profit / (Loss) from ordinary activities before tax (7+8) | (632.65) | (643.78) | (496.18) | (2,094.69) | (1,055.22) | (1,435.14) |
| 8 | Tax (expense)/credit | - | - | - | - | - | - |
| | Current Tax | | | | | | |
| | Deferred Tax | (148.35) | (150.74) | (103.36) | (503.27) | (240.68) | (421.45) |
| | Prior period Income tax adjustment | | | | | | 15.96 |
| 9 | Net Profit / (Loss) from ordinary activities after tax | (484.30) | (493.04) | (392.82) | (1,591.42) | (814.54) | (1,029.65) |
| 10 | Extraordinary items (net of tax expense) | - | - | - | - | - | - |
| 11 | Net Profit / (Loss) for the period (11+ 12) | (484.30) | (493.04) | (392.82) | (1,591.42) | (814.54) | (1,029.65) |
| 12 | Other Comprehensive Income | - | - | - | - | - | 10.73 |
| 13 | Total Comprehensive Income | (484.30) | (493.04) | (392.82) | (1,591.42) | (814.54) | (1,040.38) |
| 14 | Share of Profit/(loss) of associates | - | - | - | - | - | - |
| 15 | Minority interest | - | - | - | - | - | - |
| 16 | Paid-up equity share capital | 3,698.35 | 3,698.35 | 3,698.35 | 3,698.35 | 3,698.35 | 3,698.35 |
| | (face value Rs. 10/-) | | | | | | |
| 17.i | Earnings per share (before extraordinary items) | | | | | | |
| | (of Rs.10/- each) (not annualised): | | | | | | |
| | (a) Basic | (1.32) | (1.33) | (1.07) | (4.30) | (2.27) | (2.86) |
| | (b) Diluted | (1.32) | (1.33) | (1.12) | (4.30) | (2.27) | (2.86) |
| 17.ii | Earnings per share (after extraordinary items) | | | | | | |
| | (of Rs.10/- each) (not annualised): | | | | | | |
| | (a) Basic | (1.32) | (1.33) | (1.07) | (4.30) | (2.27) | (2.86) |
| | (b) Diluted | (1.32) | (1.33) | (1.12) | (4.30) | (2.27) | (2.86) |

NOTES:

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 4th February, 2026 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products.. Hence, segmental reporting as per IND AS-108 is not made.
- Total Turnover for the current quarter reported Rs 3393.09 Lakhs compared to Rs.3320.61 for the corresponding quarter of the previous year.
- The Loss before tax for the current quarter is Rs.632.65 Lakhs compared to Loss Before tax of Rs.496.18 Lakhs for the corresponding quarter of the previous year.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.
- The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting. Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.



For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED

Balasubba Reddy Mamilla

Whole Time Director

DIN : 01998852

Date: 04/02/2026

Place: Hyderabad

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of
OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended December 31, 2025 and year to date results for the period April 1st, 2025 to December 31, 2025 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 26209211HUDPCV9543

Place: Hyderabad

Date: 04/02/2026

